{"id":2064,"date":"2026-06-18T14:09:35","date_gmt":"2026-06-18T14:09:35","guid":{"rendered":"https:\/\/one-peptides.com\/?p=2064"},"modified":"2026-09-29T16:44:42","modified_gmt":"2026-09-29T16:44:42","slug":"slu-pp-332-what-the-research-says-about-the-err-agonist-and-exercise-mimetic","status":"publish","type":"post","link":"https:\/\/one-peptides.com\/es\/slu-pp-332-what-the-research-says-about-the-err-agonist-and-exercise-mimetic\/","title":{"rendered":"SLU-PP-332 \u2014 what the research says about the ERR agonist and “exercise mimetic”"},"content":{"rendered":"
\n\tHome<\/a>\n<\/span>\u00bb<\/span>\n\tMetabolic research<\/a>\n<\/span>\u00bb<\/span>\n\tSLU-PP-332 \u2014 what the research says about the ERR agonist and \u201cexercise mimetic\u201d\n<\/span><\/div><\/div>\n

In October 2024 the journal Nature Metabolism<\/em> published a paper that triggered a wave of headlines about an “exercise pill”. Burris’s team at Saint Louis University showed that the small organic molecule SLU-PP-332<\/strong> \u2014 a pan-agonist of ERR receptors \u2014 increased running time to exhaustion in mice by roughly 70%, without physical training. The biohacker community treated this data as a prophecy of a new generation of “exercise mimetics”. The academic community treated it exactly as it should: as an interesting signal from an animal model that requires rigorous replication and \u2014 most importantly \u2014 has never been tested in humans. In the One Peptides catalogue the molecule is available as SLU-PP-332 500 mcg<\/a>.<\/p>\n

SLU-PP-332 is a small organic molecule from the ERR pan-agonist class (Estrogen-Related Receptors \u03b1\/\u03b2\/\u03b3), developed in Thomas Burris’s laboratory at Saint Louis University. Studied in mouse models as an “exercise mimetic” candidate. No registration as a medicine, zero clinical data in humans, Research Use Only status.<\/strong><\/p>\n

Regulatory note \u2014 a critical distinction<\/strong><\/p>\n

SLU-PP-332 functions solely as a research reagent (Research Use Only)<\/strong>. The molecule is not a registered medicine<\/strong>, holds no EFSA authorisation<\/strong> and has never been tested in human clinical trials<\/strong>. Several \u201cexercise mimetics\u201d \u2014 AICAR, MOTS-c and GW501516 \u2014 are named on the WADA<\/strong> Prohibited List (section S4.4.1).<\/p><\/blockquote>\n

What SLU-PP-332 is \u2014 origin and pharmacological class<\/h2>\n

The name SLU-PP-332<\/strong> is an institutional acronym: S<\/strong>aint L<\/strong>ouis U<\/strong>niversity, P<\/strong>harmaceutical P<\/strong>robe 332<\/strong>. The molecule was designed and synthesised in the laboratory of Thomas Burris<\/strong>, one of the world’s leading specialists in nuclear receptor pharmacology. For more than two decades Burris has published work on ERR, REV-ERB, PPAR and related transcription factors regulating mitochondrial metabolism.<\/p>\n

Chemical characteristics<\/h3>\n\n\n\n\n\n\n\n\n\n\n\n
Parameter<\/strong><\/th>\nValue<\/strong><\/th>\n<\/tr>\n
Name<\/td>\nSLU-PP-332<\/td>\n<\/tr>\n
Acronym expansion<\/td>\nSaint Louis University, Pharmaceutical Probe 332<\/td>\n<\/tr>\n
Laboratory of origin<\/td>\nThomas Burris, Saint Louis University<\/td>\n<\/tr>\n
Pharmacological class<\/td>\nERR pan-agonist (ERR\u03b1 + ERR\u03b2 + ERR\u03b3)<\/td>\n<\/tr>\n
Molecular weight<\/td>\n~395 Da<\/td>\n<\/tr>\n
Molecule type<\/td>\nSmall organic molecule (NOT a peptide, NOT a steroid)<\/td>\n<\/tr>\n
Development stage<\/td>\nEarly preclinical phase \u2014 mouse models<\/td>\n<\/tr>\n
Registration status<\/td>\nNo registration as a medicine in any jurisdiction<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

What ERR receptors are \u2014 Estrogen-Related Receptors<\/h2>\n

ERR (Estrogen-Related Receptors)<\/strong> are a family of nuclear receptors discovered in 1988 by Vincent Gigu\u00e8re. The family comprises three isoforms: ERR\u03b1<\/strong> (dominant in tissues with high energy demand), ERR\u03b2<\/strong> (embryonic development and CNS), ERR\u03b3<\/strong> (skeletal muscle and cardiac muscle).<\/p>\n

The name “estrogen-related” is misleading.<\/strong> ERRs were classified as “estrogen-related” solely because of their amino acid sequence similarity to the estrogen receptor (ER\u03b1). In reality, ERRs do not bind estradiol<\/strong>. Receptor activity is regulated mainly by transcriptional coactivators, in particular PGC-1\u03b1<\/strong>.<\/p>\n

Biological functions of ERR<\/h3>\n